secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-11-22T23:59:59+00:00
Accession:  0001104659-23-120557
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada completes first two cohorts in Phase 1 for ENTR-601-44; US clinical hold remains
--------------------------------------------------------------------------------

- Completed dosing of first and second cohorts in Phase 1 trial ENTR-601-44-101 in the UK.
- Data from Phase 1 trial expected in second half of 2024.
- FDA clinical hold on IND remains in effect; FDA declined to lift hold despite additional data.
- Company plans global development for exon 44 skipping amenable DMD patients.
- Cash runway expected through 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923120557/0001104659-23-120557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923120557/tm2331388d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-120557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer